

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Boehm et al.	14 April 2009
Serial No.:	10/511,770	Group Art Unit No.: 1624
Filed:	3 March 2006	Examiner: Truong, T.
For:	NOVEL COMPOUNDS	

FILING OF AN INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., *after* three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but *before* the mailing date of Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

The Examiners attention is also drawn to related applications of Applicants in the field of p38 Kinase Inhibitors which are also shown on page 1 of the accompanying 7 page PTOL-1449 form. They include six US patent (AA to AF) and two US publications (AG to AH). The remaining six pages of citations reflect the references submitted for review in the present application.

In order to simplify the number of references and reduce duplicative submissions listed in this Information Disclosure Statement, Applicants have prepared a summary of corresponding US Patents to their respective WIPO Publications. It should be noted, Applicants only list a representative number of the corresponding US Patents and Publications and do not assert that this is a full and complete listing thereof. As the US patents are no longer required to be submitted, copies of these do not accompany this


Serial No.: 10/511,770  
Group Art Unit No.: 1624

response. Should the Examiner wish copies of any listed references please advise the undersigned at the number indicated below.

WO 01/64679	US7,235,551US 2003100756A1 US2007/0238743 US2007/0167467 US2009/0048442	WO 2006104915A2	US 2006235029A1 US 2009069318A1
WO 2006104917A2	US 7,479,558US 2006/258687A1 US 2009/048444A1	WO 02059083A2	US 2004116697A1 US 2004209901A1 US 2005203109A1 US 2008032969A1 US 2008033170A1 US 7314881B2 US 7314934B2 US 7323472B2

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017 Facsimile (610) 270-5090